This “Gastroparesis - Pipeline Insight, 2020” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Gastroparesis Understanding

Gastroparesis: Overview

Gastroparesis is a disease in which the stomach cannot empty itself of food in a normal fashion. This is a common condition in people who have had diabetes for a long time, but it may also occur in other situations. Gastroparesis is caused by nerve injury, including damage to the vagus nerve. In its normal state, the vagus nerve contracts (tightens) the stomach muscles to help move food through the digestive tract. In cases of gastroparesis, the vagus nerve is damaged by diabetes. This prevents the muscles of the stomach and intestine from working properly, which keeps food from moving from the stomach to the intestines.

Symptoms

The symptoms of gastroparesis include:
Heartburn or gastroesophageal reflux (backup of stomach contents into the esophagus)
Nausea
Vomiting undigested food
Early satiety (feeling full quickly when eating)
Abdominal bloating (enlargement)
Poor appetite and weight loss
Poor blood sugar control
Diagnosis

A diagnosis of gastroparesis is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests may first be performed to rule out other causes of delayed gastric emptying such as obstruction of the gastrointestinal tract. Additional tests are then performed to confirm a diagnosis of gastroparesis. An upper endosocpic procedure may lead to a serendipitous diagnosis of gastroparesis through the discovery of identifiable food within the stomach after the pre-procedure overnight fast.

Treatment

Treating the underlying cause of gastroparesis (such as tightening up blood glucose control in diabetes) is usually the first step in treating individuals with gastroparesis. The specific therapeutic techniques used depend upon several factors, including the severity of the disorder. Therapies that are used to treat individuals with gastroparesis include non-pharmacological steps, dietary modification, medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery. Medications that stimulate gastric emptying are called prokinetics. They are the primary treatment for individuals with gastroparesis. First-line medical treatment begins with the dopamine blockers. Of the two drugs, metoclopromide (Reglan) and domperidone (Motilitum), domperidone has a much better safety profile. Metoclopromide has serious neurological side effects, including irreversible tartive dyskinesia. Domperidone is now available in the United States through the FDA's Investigational New Drug protocol. Next are the motilin agonists, such as erythromycin.

Gastroparesis Emerging Drugs Chapters

This segment of the Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastroparesis Emerging Drugs

Tradipitant: Vanda Pharmaceuticals

Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.

Relamorelin: AbbVie

Relamorelin is a Phase 2 ghrelin agonist in development for the treatment of diabetic gastroparesis and GI functional disorders. Derived from the natural ghrelin sequence, relamorelin has been optimized to stimulate gastrointestinal (GI) motility, with greater potency and enhanced stability and pharmacokinetics. Relamorelin has completed a Phase 2 trial in diabetic gastroparesis and a Phase 2a study in chronic constipation, and additional Phase 2 trials are under way in lower GI functional disorders and diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to relamorelin for the treatment of diabetic gastroparesis.

Gastroparesis: Therapeutic Assessment

This segment of the report provides insights about the different Gastroparesis drugs segregated based on following parameters that define the scope of the report.

Major Players in Gastroparesis

There are approx. 30+ key companies which are developing the therapies for Gastroparesis. The companies which have their Gastroparesis drug candidates in the most advanced stage, i.e. phase III include, AbbVie.

Phases

This report covers around 30+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravitreal
Subretinal
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastroparesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroparesis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroparesis drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Gastroparesis.
In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
Gastroparesis Report Insights
Gastroparesis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Gastroparesis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Gastroparesis drugs?
How many Gastroparesis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroparesis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastroparesis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Gastroparesis and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
RaQualia Pharma Inc.
Vanda Pharmaceuticals
Janssen Inc.
UCB Pharma
Tranzyme, Inc.
Theravance Biopharma
Targacept Inc.
Takeda
Merck Sharp & Dohme Corp.
PTC Therapeutics
Otsuka Pharmaceutical
Neurogastrx, Inc.
Motus Therapeutics, Inc.
Millennium Pharmaceuticals
Ironwood Pharmaceuticals, Inc.
GlaxoSmithKline
Forest Laboratories
Evoke Pharma
Eli Lilly and Company
CinDome Pharma, Inc.
Chugai Pharma USA
Bird Rock Bio, Inc.
Allergan
Key Products
RQ-00000010
Tradipitant
Prucalopride
Reglan ODT
TZP-102
Velusetrag
TC-6499
TAK-954
Sitagliptin
CNSA-001
13C-uracil
NG101
RM-131
TAK-906
IW-9179
Camicinal
Itopride
Metoclopramide Nasal Spray
tadalafil
CIN-102
GM-611
Nimacimab
Relamorelin